Skip to main content
. Author manuscript; available in PMC: 2015 Dec 18.
Published in final edited form as: Pharmacogenomics J. 2013 Apr 16;14(2):160–170. doi: 10.1038/tpj.2013.13

Table 4.

Pharmacogenomic diversity and response to cisplatin and platinum compounds

Drug Drug responsea Gene Variant CH Position Functional
annotation		 Allelesb African
ancestryc 		European
ancestryc 		Bonferroni
P-valued,e
Cisplatin TOXICITY/ADR
Increased risk of
hearing loss
(Ototoxicity)		 COMT rs9332377 22 18335692 Intron A/G 0.327 0.168 5.40E-14
TOXICITY/ADR
Decreased risk of
severe neutropenia		 XRCC1 rs25487 19 48747566 Coding NONSYN
Q399R		 A/G 0.148 0.351 3.37E-22
TOXICITY/ADR
Increased likelihood
of drug toxicity		 MTR rs1805087 1 235115123 Coding NONSYN
D919G		 G/A 0.272 0.187 0.0142
EFFICACY
Increased response		 MTHFR rs1801133 1 11778965 Coding NONSYN
A222V		 A/G 0.069 0.348 2.57E-51
Carboplatin TOXICITY/ADR
Decreased risk of
severe neutropenia		 XRCC1 rs25487 19 48747566 Coding NONSYN
Q399R		 A/G 0.148 0.351 3.37E-22
EFFICACY
Increased response		 MTHFR rs1801133 1 11778965 Coding NONSYN
A222V		 A/G 0.069 0.348 2.57E-51
Oxaliplatin TOXICITY/ADR
Decreased risk of
severe neutropenia		 XRCC1 rs25487 19 48747566 Coding NONSYN
Q399R		 A/G 0.148 0.351 3.37E-22
EFFICACY
Increased response		 MTHFR rs1801133 1 11778965 Coding NONSYN
A222V		 A/G 0.069 0.348 2.57E-51

Abbreviations: ADR, adverse drug reaction; CH, chromosome; SNP, single-nucleotide polymorphism.

a

The clinical annotations of the relevant pharmacogenomics variants were curated from PharmGKB20 and published studies.28–30,33

b

Minor allele/Major allele.

c

Variant minor allele frequency (MAF).

d

Corrected P-value (corrected for 4209 SNPs).

e

Statistical test—Fisher’s exact test.